Alpelisib
About
Therapy type: Targeted therapy
Therapy strategy: PI3K/AKT/mTOR inhibition
Mappings
NCI Thesaurus: Alpelisib (coding:ncit:C94214)
RxNorm: alpelisib (coding:rxcui:2169285, coding:omop:1396423)
SNOMED: Alpelisib (coding:sctid:788050002, coding:omop:37312644)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| FDA (1) | ER positive, HER2-negative, PIK3CA Somatic variants | Invasive Breast Carcinoma | Alpelisib, Fulvestrant | |
| FDA (1) | HER2-negative, PIK3CA Somatic variants, PR positive | Invasive Breast Carcinoma | Alpelisib, Fulvestrant | |
| FDA (1) | ER positive, HER2-negative, PIK3CA Somatic variants, PR positive | Invasive Breast Carcinoma | Alpelisib, Fulvestrant | |
| EMA (1) | ER positive, HER2-negative, PIK3CA Somatic variants | Invasive Breast Carcinoma | Alpelisib, Fulvestrant | |
| EMA (1) | HER2-negative, PIK3CA Somatic variants, PR positive | Invasive Breast Carcinoma | Alpelisib, Fulvestrant | |
| EMA (1) | ER positive, HER2-negative, PIK3CA Somatic variants, PR positive | Invasive Breast Carcinoma | Alpelisib, Fulvestrant |